Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
4-1BB (CD137) is an inducible costimulatory receptor that promotes expansion and survival of activated T cells; and IgG-based 4-1BB-agonistic monoclonal antibodies exhibited potent antitumor activity in clinical trials. However, the clinical development of those antibodies is restricted by major off-tumor toxicities associated with FcγR interactions. We have recently generated an EGFR-targeted 4-1BB-agonistic trimerbody that demonstrated strong antitumor activity and did not induce systemic inflammatory cytokine secretion and hepatotoxicity associated with first-generation 4-1BB agonists. Here, we generate a bispecific 4-1BB-agonistic trimerbody targeting the carcinoembryonic antigen (CEA) that is highly expressed in cancers of diverse origins. The CEA-targeted anti-4-1BB-agonistic trimerbody consists of three 4-1BB-specific single-chain fragment variable antibodies and three anti-CEA single-domain antibodies positioned around a murine collagen XVIII-derived homotrimerization domain. The trimerbody was produced as a homogenous, non-aggregating, soluble protein purifiable by standard affinity chromatographic methods. The purified trimerbody was found to be trimeric in solution, very efficient at recognizing 4-1BB and CEA, and potently costimulating T cells in vitro in the presence of CEA. Therefore, trimerbody-based tumor-targeted 4-1BB costimulation is a broadly applicable and clinically feasible approach to enhance the costimulatory environment of disseminated tumor lesions.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1080/2162402X.2017.1371896
- https://doi.org//10.1158/2159-8290.CD-18-0367
- https://doi.org//10.1182/blood-2017-06-741041
- https://doi.org//10.1002/eji.201445388
- https://doi.org//10.1146/annurev-immunol-042718-041407
- https://doi.org//10.1038/nm0697-682
- https://doi.org//10.1158/1078-0432.CCR-12-2065
- https://doi.org//10.1080/2162402X.2016.1238540
- https://doi.org//10.1038/mt.2011.145
- https://doi.org//10.1038/s41467-018-07195-w
- https://doi.org//10.1006/scbi.1998.0119
- https://doi.org//10.4049/jimmunol.1203010
- https://doi.org//10.1158/0008-5472.CAN-03-3935
- https://doi.org//10.1038/srep28643
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (9)
CATEGORIES
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity